6 unchanged sentences
Amended and Restated Bylaws
−Removed: Offer Letter between Mardi C.
−Removed: Dier and Ultragenyx Pharmaceutical Inc.
−Removed: dated August 28, 2020.
−Removed: Amendment dated October 9, 2020 to the Offer Letter between Mardi C.
−Removed: Dier and Ultragenyx Pharmaceutical Inc.
−Removed: dated August 28, 2020
−Removed: Amendment, dated as of August 28, 2020, to Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc.
−Removed: dated March 5, 2020.
−Removed: Amendment No.
−Removed: 2 dated October 8, 2020 to the Transition Letter Agreement between Shalini Sharp and Ultragenyx Pharmaceutical Inc.
−Removed: dated as of March 5, 2020, as amended on August 28, 2020
−Removed: Fourth Amended and Restated Amendment to Lease Agreement between Ultragenyx Pharmaceutical Inc.
−Removed: and ARE-MA Region No.
+Added: Form of Common Stock Certificate
+Added: Form of Indenture
+Added: Form of Performance Stock Unit Agreement (2021)
+Added: Employment Inducement Plan
+Added: Form of Non Statutory Stock Option Agreement (Inducement Plan)
+Added: Form of Non Statutory Stock Option Agreement (Inducement Plan) (ex-US)
+Added: Form of Restricted Stock Unit Agreement (Inducement Plan)
+Added: Form of Restricted Stock Unit Agreement (Inducement Plan) (ex-US)
Certification of Principal Executive Officer Required Under Rule 13a-14(a) or Rule 15d-14(a) of the Exchange Act
8 unchanged sentences
Cover Page Interactive Data File, formatted in Inline XBRL (included in Exhibit 101).
+Added: # Indicates management contract or compensatory plan.
+Added: † Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
* The certification attached as Exhibit 32.1 that accompanies this Quarterly Report is furnished to, and not deemed filed with, the SEC and is not to be incorporated by reference into any filing of the Registrant under the Securities Act or the Exchange Act, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
1 unchanged sentence
ULTRAGENYX PHARMACEUTICAL I NC .
−Removed: October 27, 2020
Kakkis, M.D., Ph.D.
1 unchanged sentence
(Duly Authorized Officer)
−Removed: October 27, 2020
+Added: Executive Vice President and Chief Financial Officer
+Added: (Principal Financial Officer)
/s/ Theodore A.
−Removed: Senior Vice President and Corporate Controller
+Added: Senior Vice President and Chief Accounting Officer
(Principal Accounting Officer)
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.